EGFR and non-small cell lung carcinoma: Based on the impressive hazard ratio of 0.20 (95% CI, 0.14-0.30; P < .001), the Food and Drug Administration approved adjuvant osimertinib for resected NSCLC with EGFR-positive exon 19 deletion (Ex19del) or exon 21 L858R (L858R) in December 2020.